BrainStorm

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees and has raised a total of $67.13M across 17 funding rounds. The company went public on NASDAQ in October 2003, marking a significant milestone in its journey to develop treatments for neurodegenerative diseases.

Business overview

BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous stem cell therapeutics for neurodegenerative disorders, primarily amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Its core technology, NurOwn®, involves transforming a patient's own mesenchymal stem cells into neurotrophic factor-secreting cells, which are designed to deliver growth factors to affected areas. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers, patients, and pharmaceutical industries.

Strategic signal

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize the development of NurOwn® for ALS treatment, following discussions with the US FDA. This indicates a focused effort to advance its lead therapeutic candidate and navigate regulatory pathways, signaling a critical strategic pivot for the company in its pursuit of bringing NurOwn® to market.

Company Intelligence Q&A

What was the outcome of the FDA advisory committee meeting regarding NurOwn® for ALS?

In September 2023, FDA advisers voted against the experimental ALS treatment NurOwn®, as reported by finance.yahoo.com.

What was the key announcement from BrainStorm Cell Therapeutics in October 2023?

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize NurOwn® for the treatment of ALS, following discussions with the US FDA regarding its development plan.

Did BrainStorm Cell Therapeutics regain compliance with Nasdaq listing requirements?

In October 2024, BrainStorm Cell Therapeutics regained compliance with the Nasdaq minimum bid price requirement.

What was the nature of the funding received in March 2020?

In March 2020, BrainStorm Cell Therapeutics raised capital from ABBHI INVESTMENTS, LLC through a common stock sale.

What was the focus of BrainStorm's presentations at the 2024 Annual NEALS Meeting?

In October 2024, BrainStorm Cell Therapeutics presented positive survival data from its NurOwn® Expanded Access Program at the 2024 Annual NEALS Meeting, and also announced presentations on NurOwn® at the event in September 2024.